MicroRNA-223 and oxidant-antioxidant status in leukemia patients

Abstract

Author(s): Zainab M. Hillel and Zainab N. Al-Abady*

The aim of the study was to elucidate miRNA-223 expression in patients with acute myeloid leukemia, acute lymphocytic leukemia and chronic myeloid leukemia and regulate miRNA-223 expression in oxidative stress based on current research. 40 patients with Acute Lymphoblastic Leukemia (ALL), 40 patients with acute myeloid leukemia (AML), 30 patients with Chronic Myeloid Leukemia (CML) and 40 healthy subjects served as controls. A colorimetric method was used to measure Catalase (CAT) and Malondialdehyde (MDA) activity. The serum concentrations of Heme Oxygenase 1 (HMOX1) were measured by Enzyme Immunoassay (ELISA). A quantitative polymerase chain reaction was used to determine serum miRNA-223 expression. It was found that CAT activity was significantly reduced in the patient groups compared to the control group (p<0.05), but MDA and HMOX1 concentrations were significantly higher in the patient groups compared to the control group (p<0, 05). 0.05).When patient groups were compared to control groups, miRNA-223 expression increased in patients (p<0.05). It has been reported that miRNA-223 expression is associated with the development of leukemia diseases such as ALL, AML and CML. In people with leukemia, especially AML. The oxidative stress biomarker is significantly affected by increased miRNA_223 expression.

Share this article